U
K2X Technology & Life Science, Inc.
KBPH
OTC PK
D
Sell
8/31/2022Downgrade
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 8/31/2022 due to a noticeable decline in the volatility index and total return index.
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 8/31/2022 due to a noticeable decline in the volatility index and total return index.
D
Sell
8/16/2022Upgraded
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 8/16/2022 due to an increase in the volatility index.
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 8/16/2022 due to an increase in the volatility index.
D
Sell
6/10/2022Downgrade
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 6/10/2022 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $0.04 to $0.01, EBIT declined 5.39% from -$352.7 to -$371.7, and operating cash flow declined 0.69% from -$1.44M to -$1.45M.
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 6/10/2022 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $0.04 to $0.01, EBIT declined 5.39% from -$352.7 to -$371.7, and operating cash flow declined 0.69% from -$1.44M to -$1.45M.
D
Sell
11/22/2021Upgraded
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 11/22/2021 due to an increase in the total return index, efficiency index and volatility index. Net income increased 398.41% from -$333.8 to $996.1, and total capital increased 26.71% from $8.54M to $10.82M.
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 11/22/2021 due to an increase in the total return index, efficiency index and volatility index. Net income increased 398.41% from -$333.8 to $996.1, and total capital increased 26.71% from $8.54M to $10.82M.
D
Sell
9/2/2021Downgrade
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 9/2/2021 due to a decline in the volatility index and valuation index.
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 9/2/2021 due to a decline in the volatility index and valuation index.
D
Sell
8/16/2021Upgraded
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 8/16/2021 due to an increase in the volatility index.
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D+ from D on 8/16/2021 due to an increase in the volatility index.
D
Sell
8/11/2021Upgraded
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D from D- on 8/11/2021 due to a significant increase in the efficiency index, growth index and volatility index. Net income increased 3,895% from -$4 to $151.8, earnings per share increased from -$0.0005 to $0.0026, and operating cash flow increased 120.62% from -$1.97M to $405.6.
Kyto Technology and Life Science, Inc. (KBPH) was upgraded to D from D- on 8/11/2021 due to a significant increase in the efficiency index, growth index and volatility index. Net income increased 3,895% from -$4 to $151.8, earnings per share increased from -$0.0005 to $0.0026, and operating cash flow increased 120.62% from -$1.97M to $405.6.
D
Sell
2/17/2021Downgrade
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D- from D on 2/17/2021 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 124.78% from -$874.9 to -$1.97M, EBIT declined 107.81% from -$160.1 to -$332.7, and earnings per share declined from $0.02 to -$0.0005.
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D- from D on 2/17/2021 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 124.78% from -$874.9 to -$1.97M, EBIT declined 107.81% from -$160.1 to -$332.7, and earnings per share declined from $0.02 to -$0.0005.
D
Sell
6/7/2019Downgrade
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 6/7/2019 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 27.81% from -$57.9 to -$74.
Kyto Technology and Life Science, Inc. (KBPH) was downgraded to D from D+ on 6/7/2019 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 27.81% from -$57.9 to -$74.
D
Sell
8/16/2017Downgrade
Kyto Biopharma, Inc. (KBPH) was downgraded to D+ from C- on 8/16/2017 due to a decline in the growth index. Operating cash flow declined 158.06% from -$3.1 to -$8, and earnings per share declined from -$0.0076 to -$0.01.
Kyto Biopharma, Inc. (KBPH) was downgraded to D+ from C- on 8/16/2017 due to a decline in the growth index. Operating cash flow declined 158.06% from -$3.1 to -$8, and earnings per share declined from -$0.0076 to -$0.01.
C
Hold
6/30/2017Upgraded
Kyto Biopharma, Inc. (KBPH) was upgraded to C- from D+ on 6/30/2017 due to a noticeable increase in the growth index, solvency index and total return index. Operating cash flow increased 79.47% from -$15.1 to -$3.1, EBIT increased 23.47% from -$31.1 to -$23.8, and earnings per share increased from -$0.0099 to -$0.0077.
Kyto Biopharma, Inc. (KBPH) was upgraded to C- from D+ on 6/30/2017 due to a noticeable increase in the growth index, solvency index and total return index. Operating cash flow increased 79.47% from -$15.1 to -$3.1, EBIT increased 23.47% from -$31.1 to -$23.8, and earnings per share increased from -$0.0099 to -$0.0077.
D
Sell
5/16/2017Upgraded
Kyto Biopharma, Inc. (KBPH) was upgraded to D+ from D on 5/16/2017 due to an increase in the volatility index.
Kyto Biopharma, Inc. (KBPH) was upgraded to D+ from D on 5/16/2017 due to an increase in the volatility index.
D
Sell
2/15/2017Downgrade
Kyto Biopharma, Inc. (KBPH) was downgraded to D from D+ on 2/15/2017 due to a decline in the growth index and total return index. Operating cash flow declined 308.11% from -$3.7 to -$15.1, earnings per share declined from -$0.0062 to -$0.01, and EBIT declined 59.49% from -$19.5 to -$31.1.
Kyto Biopharma, Inc. (KBPH) was downgraded to D from D+ on 2/15/2017 due to a decline in the growth index and total return index. Operating cash flow declined 308.11% from -$3.7 to -$15.1, earnings per share declined from -$0.0062 to -$0.01, and EBIT declined 59.49% from -$19.5 to -$31.1.
D
Sell
11/18/2016Downgrade
Kyto BioPharma Inc. (KBPH) was downgraded to D+ from C- on 11/18/2016 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from -$0.0062 to -$0.01.
Kyto BioPharma Inc. (KBPH) was downgraded to D+ from C- on 11/18/2016 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from -$0.0062 to -$0.01.
C
Hold
8/3/2016Downgrade
Kyto BioPharma Inc. (KBPH) was downgraded to C- from C on 8/3/2016 due to a decline in the volatility index.
Kyto BioPharma Inc. (KBPH) was downgraded to C- from C on 8/3/2016 due to a decline in the volatility index.
C
Hold
7/5/2016Upgraded
Kyto BioPharma Inc. (KBPH) was upgraded to C from C- on 7/5/2016 due to a significant increase in the efficiency index, solvency index and growth index.
Kyto BioPharma Inc. (KBPH) was upgraded to C from C- on 7/5/2016 due to a significant increase in the efficiency index, solvency index and growth index.
C
Hold
2/17/2016Downgrade
Kyto BioPharma Inc. (KBPH) was downgraded to C- from C on 2/17/2016 due to a large decline in the growth index.
Kyto BioPharma Inc. (KBPH) was downgraded to C- from C on 2/17/2016 due to a large decline in the growth index.
C
Hold
12/31/2015None
K2X Technology & Life Science, Inc. (KBPH) was downgraded to C from U on 12/31/2015.
K2X Technology & Life Science, Inc. (KBPH) was downgraded to C from U on 12/31/2015.
